Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trial

Shaukat Ali, Elisha Shalim, Farah Farhan, Fatima Anjum, Ayesha Ali, Syed Muneeb Uddin, Faisal Shahab, Mustafa Haider, Iqra Ahmed, Mir Rashid Ali, Sadaf Khan, Sadia Rao, Kabeer Guriro, Saud Elahi, Muhammad Ali, Tehreem Mushtaq, Muneeba Ahsan Sayeed, Sheikh Muhammad Muhaymin, Shoba Luxmi, Saifullah, Saeed Qureshi, Shaukat Ali, Elisha Shalim, Farah Farhan, Fatima Anjum, Ayesha Ali, Syed Muneeb Uddin, Faisal Shahab, Mustafa Haider, Iqra Ahmed, Mir Rashid Ali, Sadaf Khan, Sadia Rao, Kabeer Guriro, Saud Elahi, Muhammad Ali, Tehreem Mushtaq, Muneeba Ahsan Sayeed, Sheikh Muhammad Muhaymin, Shoba Luxmi, Saifullah, Saeed Qureshi

Abstract

Background: COVID-19 poses a global health challenge with more than 325 million cumulative cases and above 5 million cumulative deaths reported till January 17, 2022, by the World Health Organization. Several potential treatments to treat COVID-19 are under clinical trials including antivirals, steroids, immunomodulators, non-specific IVIG, monoclonal antibodies, and passive immunization through convalescent plasma. The need to produce anti-COVID-19 IVIG therapy must be continued, alongside the current treatment modalities, considering the virus is still mutating into variants of concern. In this context, as the present study will exploit pooled diversified convalescent plasma collected from recovered COVID-19 patients, the proposed hyperimmune Anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy would be able to counter new infectious COVID-19 variants by neutralizing the virus particles. After the successful outcome of the phase I/II clinical trial of C-IVIG, the current study aims to further evaluate the safety and efficacy of single low dose C-IVIG in severe COVID-19 patients for its phase II/III clinical trial.

Methods: This is a phase II/III, adaptive, multi-center, single-blinded, randomized controlled superiority trial of SARS-CoV-2 specific polyclonal IVIG (C-IVIG). Patients fulfilling the eligibility criteria will be block-randomized using a sealed envelope system to receive either 0.15 g/Kg C-IVIG with standard of care (SOC) or standard of care alone in 2:1 ratio. The patients will be followed-up for 28 days to assess the primary and secondary outcomes.

Discussion: This is a phase II/III clinical trial evaluating safety and efficacy of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) in severe COVID-19 patients. This study will provide clinical evidence to use C-IVIG as one of the first-line therapeutic options for severe COVID-19 patients.

Trial registration: Registered at clinicaltrial.gov with NCT number NCT04891172 on May 18, 2021.

Keywords: Anti-COVID-19 IVIG; Hyperimmune; Intravenous; Novel coronavirus; Passive immunization; Pneumonia; Polyclonal antibodies; Pooled convalescent plasma; Randomized controlled trial; SARS CoV-2.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Consort flow diagram of the trial design

References

    1. WHO . WHO Director-General’s opening remarks at the media briefing on COVID-19—11 March 2020. 2020.
    1. Sakoulas G, Geriak M, Kullar R, Greenwood KL, Habib M, Vyas A, Ghafourian M, Dintyala VN, Haddad F. Intravenous immunoglobulin plus methylprednisolone mitigate respiratory morbidity in coronavirus disease 2019. Crit Care Explor. 2020;2(11):3. doi: 10.1097/CCE.0000000000000280.
    1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017.
    1. Garcia-Beltran WF, Lam EC, Denis KS, Nitido AD, Garcia ZH, Hauser BM, Feldman J, Pavlovic MN, Gregory DJ, Poznansky MC, Sigal A. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184(9):2372–2383. doi: 10.1016/j.cell.2021.03.013.
    1. Franchini M. Convalescent plasma therapy for managing infectious diseases: a narrative review. Ann Blood. 2021;6:17. doi: 10.21037/aob-2020-cp-03.
    1. Wang JT, Sheng WH, Fang CT, et al. Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerg Infect Dis. 2004;10(5):818. doi: 10.3201/eid1005.030640.
    1. Arabi YM, Arifi AA, Balkhy HH, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med. 2014;160(6):389–397. doi: 10.7326/M13-2486.
    1. Martinez JI, Sanchez HF, Velandia JA, Urbina Z, Florian MC, Martínez MA, et al. Treatment with IgM-enriched immunoglobulin in sepsis: a matched case-control analysis. J Crit Care. 2021;64:120–124. doi: 10.1016/j.jcrc.2021.03.015.
    1. Jawhara S. Could intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients? Int J Mol Sci. 2020;21(7):2272. doi: 10.3390/ijms21072272.
    1. de Alwis R, Chen S, Gan ES, Ooi EE. Impact of immune enhancement on COVID-19 polyclonal hyperimmune globulin therapy and vaccine development. EbioMedicine. 2020;16:102768. doi: 10.1016/j.ebiom.2020.102768.
    1. Ali S, Uddin SM, Shalim E, Sayeed MA, Anjum F, Saleem F, Muhaymin SM, Ali A, Ali MR, Ahmed I, Mushtaq T. Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: A phase I/II randomized control trial. EClinicalMedicine. 2021;36:100926. doi: 10.1016/j.eclinm.2021.100926.
    1. Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med. 2016;375(1):65–74. doi: 10.1056/NEJMra1510061.
    1. Ali S, Uddin SM, Ali A, Anjum F, Ali R, Shalim E, et al. Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma. Immunotherapy. 2021;13(5):397–407. doi: 10.2217/imt-2020-0263.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe